Podcast

Advances in Metastatic HER2-Positive Breast Cancer

Author(s):

OncLive Staff

Dr Gradishar and colleagues highlight key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

Related Videos
Ruth M. O’Regan, MD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Sheldon M. Feldman, MD
Dana Zakalik, MD
Alberto Montero, MD, MBA, CPHQ
Jairam Krishnamurthy, MD, FACP
Deena Mary Atieh Graham, MD
Sheldon M. Feldman, MD
Sheldon M. Feldman, MD
In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer, highlighting the need for holistic care that addresses both physiological and psychological aspects of treatment while reinforcing the value of strong relationships between primary care physicians and specialists.
Related Content
Jairam Krishnamurthy, MD, FACP
November 22nd 2024

Category 1 Recommendation of Ribociclib Plus an AI Represents Huge Advancement in Breast Cancer

Susana M. Campos, MD, MPH
November 21st 2024

Trastuzumab Deruxtecan Advances HER2+ Gynecologic Cancer Care: With Susana M. Campos, MD, MPH

Lubna Naaz Chaudhary, MD, MS, associate professor, medicine, Medical College of Wisconsin
November 19th 2024

Ongoing and Planned Research Build on Prior Advancements in ER+/HER2– Breast Cancer

Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB, head, Division of Radiotherapy and Imaging, The Institute of Cancer Research; fellow, the Royal College of Physicians, the Royal College of Radiologists
November 18th 2024

HPV16-Targeted Immunotherapy Is Set to Personalize HNSCC Management: With Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB

Kari Wisinski, MD, the Endowed Professor of Hematology and Oncology and chief of the Division of Hematology, Medical Oncology and Palliative Care in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health in Madison
November 12th 2024

Genomic Predictors Inform the Evolving Role of Chemotherapy in Breast Cancer Management

BT7480 in Nectin-4+, CD137+ Tumors | Image Credit: © Katsyarina - stock.adobe.com
November 7th 2024

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors